Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$110.0 million.

  • BridgeBio Pharma's Free Cash Flow rose 3910.23% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$585.9 million, marking a year-over-year decrease of 2976.19%. This contributed to the annual value of -$521.7 million for FY2024, which is 139.26% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Free Cash Flow stood at -$110.0 million, which was up 3910.23% from -$80.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Free Cash Flow ranged from a high of $74.6 million in Q2 2024 and a low of -$220.2 million during Q1 2024
  • Moreover, its 5-year median value for Free Cash Flow was -$135.9 million (2022), whereas its average is -$125.1 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Free Cash Flow crashed by 24605.69% in 2023, and later soared by 16565.61% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Free Cash Flow (Quarter) stood at -$136.4 million in 2021, then surged by 31.07% to -$94.0 million in 2022, then plummeted by 33.19% to -$125.3 million in 2023, then plummeted by 55.98% to -$195.4 million in 2024, then skyrocketed by 43.67% to -$110.0 million in 2025.
  • Its Free Cash Flow stands at -$110.0 million for Q3 2025, versus -$80.9 million for Q2 2025 and -$199.6 million for Q1 2025.